| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 53 | 2023 | 5230 | 5.300 |
Why?
|
| Lung Neoplasms | 75 | 2023 | 13112 | 5.280 |
Why?
|
| Pneumonia | 19 | 2022 | 2133 | 4.130 |
Why?
|
| Lung Diseases, Interstitial | 25 | 2022 | 808 | 2.730 |
Why?
|
| Tomography, X-Ray Computed | 77 | 2022 | 20121 | 2.360 |
Why?
|
| Tumor Burden | 14 | 2021 | 1917 | 2.240 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2022 | 5532 | 2.070 |
Why?
|
| Antineoplastic Agents | 20 | 2020 | 13691 | 1.710 |
Why?
|
| Awards and Prizes | 3 | 2020 | 375 | 1.500 |
Why?
|
| Thymus Hyperplasia | 3 | 2015 | 30 | 1.470 |
Why?
|
| Exhalation | 9 | 2019 | 167 | 1.450 |
Why?
|
| Lung | 41 | 2022 | 9858 | 1.440 |
Why?
|
| Diagnostic Imaging | 12 | 2019 | 3503 | 1.420 |
Why?
|
| Immunotherapy | 18 | 2021 | 4437 | 1.340 |
Why?
|
| Thymus Neoplasms | 4 | 2018 | 268 | 1.310 |
Why?
|
| Solitary Pulmonary Nodule | 4 | 2020 | 266 | 1.280 |
Why?
|
| Thoracic Neoplasms | 3 | 2021 | 268 | 1.250 |
Why?
|
| Quinazolines | 5 | 2016 | 1356 | 1.240 |
Why?
|
| Antibodies, Monoclonal | 12 | 2018 | 9272 | 1.210 |
Why?
|
| Radiology | 10 | 2020 | 2099 | 1.210 |
Why?
|
| Radiography, Thoracic | 12 | 2020 | 1265 | 1.090 |
Why?
|
| Lung Diseases | 11 | 2022 | 1887 | 1.030 |
Why?
|
| Pseudolymphoma | 2 | 2015 | 30 | 0.990 |
Why?
|
| Sarcoidosis, Pulmonary | 2 | 2018 | 43 | 0.960 |
Why?
|
| Radiographic Image Enhancement | 7 | 2014 | 885 | 0.940 |
Why?
|
| Neoplasms | 22 | 2021 | 21675 | 0.900 |
Why?
|
| Melanoma | 10 | 2019 | 5508 | 0.870 |
Why?
|
| Alveolitis, Extrinsic Allergic | 2 | 2021 | 61 | 0.840 |
Why?
|
| Neuroendocrine Tumors | 3 | 2018 | 594 | 0.830 |
Why?
|
| Thoracic Diseases | 2 | 2017 | 97 | 0.820 |
Why?
|
| Granuloma | 3 | 2018 | 319 | 0.800 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2020 | 154 | 0.790 |
Why?
|
| Aged, 80 and over | 65 | 2022 | 57744 | 0.780 |
Why?
|
| Aged | 103 | 2022 | 163178 | 0.770 |
Why?
|
| Molecular Targeted Therapy | 10 | 2021 | 2727 | 0.740 |
Why?
|
| Humans | 201 | 2023 | 743811 | 0.730 |
Why?
|
| Radiation Pneumonitis | 2 | 2020 | 104 | 0.730 |
Why?
|
| Middle Aged | 106 | 2022 | 213241 | 0.690 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 6 | 2022 | 451 | 0.670 |
Why?
|
| Mutation | 27 | 2022 | 29777 | 0.620 |
Why?
|
| Thymus Gland | 3 | 2015 | 1266 | 0.620 |
Why?
|
| Pulmonary Embolism | 7 | 2019 | 2375 | 0.620 |
Why?
|
| Radiography | 8 | 2021 | 7010 | 0.620 |
Why?
|
| Bronchiectasis | 3 | 2022 | 128 | 0.610 |
Why?
|
| Diaphragm | 5 | 2019 | 349 | 0.600 |
Why?
|
| Lymphoma | 2 | 2016 | 1875 | 0.600 |
Why?
|
| Male | 115 | 2022 | 349776 | 0.600 |
Why?
|
| Disease Progression | 17 | 2021 | 13273 | 0.590 |
Why?
|
| Female | 123 | 2022 | 380020 | 0.580 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2015 | 8939 | 0.560 |
Why?
|
| Periodicals as Topic | 4 | 2020 | 1429 | 0.560 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 6363 | 0.540 |
Why?
|
| Tomography, Spiral Computed | 4 | 2005 | 280 | 0.540 |
Why?
|
| Adult | 84 | 2022 | 213889 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7270 | 0.520 |
Why?
|
| Pulmonary Emphysema | 6 | 2021 | 672 | 0.510 |
Why?
|
| Ovarian Diseases | 3 | 2006 | 139 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2020 | 579 | 0.490 |
Why?
|
| Gene Rearrangement | 2 | 2016 | 1179 | 0.490 |
Why?
|
| Mediastinal Cyst | 1 | 2014 | 29 | 0.490 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2018 | 3142 | 0.480 |
Why?
|
| Internship and Residency | 5 | 2019 | 5787 | 0.450 |
Why?
|
| Respiratory Function Tests | 10 | 2019 | 1615 | 0.450 |
Why?
|
| Retrospective Studies | 45 | 2022 | 77410 | 0.430 |
Why?
|
| Exons | 5 | 2020 | 2438 | 0.420 |
Why?
|
| Neoplasm Staging | 12 | 2021 | 11036 | 0.420 |
Why?
|
| Positron-Emission Tomography | 5 | 2015 | 6237 | 0.410 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 484 | 0.410 |
Why?
|
| Thorax | 3 | 2020 | 547 | 0.400 |
Why?
|
| Emphysema | 2 | 2021 | 247 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 2037 | 0.390 |
Why?
|
| Japan | 4 | 2019 | 1360 | 0.390 |
Why?
|
| Pregnancy, Ectopic | 2 | 2003 | 141 | 0.390 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 608 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5170 | 0.380 |
Why?
|
| Treatment Outcome | 31 | 2020 | 63042 | 0.380 |
Why?
|
| Pyridines | 3 | 2017 | 2827 | 0.370 |
Why?
|
| Mucin-5B | 5 | 2019 | 141 | 0.360 |
Why?
|
| Pyrazoles | 3 | 2017 | 1970 | 0.360 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 9 | 2022 | 3047 | 0.360 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 2924 | 0.350 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 6895 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2022 | 1691 | 0.350 |
Why?
|
| Hemosiderosis | 1 | 2010 | 71 | 0.350 |
Why?
|
| Respiration | 5 | 2019 | 1653 | 0.340 |
Why?
|
| Genomics | 7 | 2022 | 5714 | 0.330 |
Why?
|
| Survival Rate | 9 | 2021 | 12786 | 0.330 |
Why?
|
| Peristalsis | 2 | 2006 | 60 | 0.330 |
Why?
|
| Medical Oncology | 3 | 2021 | 2267 | 0.330 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2015 | 1184 | 0.320 |
Why?
|
| Leiomyoma | 2 | 2005 | 730 | 0.320 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2006 | 169 | 0.310 |
Why?
|
| Sirolimus | 1 | 2015 | 1565 | 0.310 |
Why?
|
| Uterine Contraction | 2 | 2006 | 93 | 0.310 |
Why?
|
| Inhalation | 2 | 2005 | 143 | 0.300 |
Why?
|
| Bronchial Diseases | 2 | 2006 | 151 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11524 | 0.300 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 2291 | 0.290 |
Why?
|
| Pleura | 2 | 2019 | 235 | 0.290 |
Why?
|
| Observer Variation | 5 | 2020 | 2592 | 0.290 |
Why?
|
| Pulmonary Fibrosis | 4 | 2021 | 530 | 0.290 |
Why?
|
| Iohexol | 3 | 2014 | 196 | 0.290 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 446 | 0.280 |
Why?
|
| Sarcoidosis | 2 | 2017 | 506 | 0.280 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 2883 | 0.270 |
Why?
|
| Cohort Studies | 21 | 2022 | 40545 | 0.270 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 1049 | 0.270 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2015 | 1052 | 0.270 |
Why?
|
| Smoking | 8 | 2016 | 8984 | 0.270 |
Why?
|
| Computers, Handheld | 2 | 2004 | 208 | 0.270 |
Why?
|
| Prognosis | 14 | 2020 | 29052 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6539 | 0.260 |
Why?
|
| Kidney Neoplasms | 5 | 2018 | 4260 | 0.250 |
Why?
|
| Hemorrhage | 4 | 2017 | 3458 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 35409 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 9239 | 0.250 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 19894 | 0.250 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2020 | 3712 | 0.250 |
Why?
|
| Uterine Neoplasms | 2 | 2005 | 1513 | 0.250 |
Why?
|
| Incidence | 8 | 2021 | 20948 | 0.250 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4251 | 0.240 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2006 | 962 | 0.240 |
Why?
|
| Artifacts | 5 | 2006 | 1904 | 0.240 |
Why?
|
| Forced Expiratory Volume | 4 | 2019 | 1740 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 4033 | 0.240 |
Why?
|
| Contrast Media | 8 | 2014 | 5301 | 0.230 |
Why?
|
| Molecular Imaging | 1 | 2011 | 821 | 0.230 |
Why?
|
| Image Enhancement | 2 | 2013 | 2915 | 0.230 |
Why?
|
| Hemangioendothelioma | 1 | 2004 | 121 | 0.230 |
Why?
|
| Adnexal Diseases | 1 | 2004 | 102 | 0.220 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2003 | 94 | 0.220 |
Why?
|
| Bronchi | 2 | 2006 | 840 | 0.220 |
Why?
|
| Computer Communication Networks | 1 | 2004 | 296 | 0.210 |
Why?
|
| Diagnosis, Differential | 8 | 2014 | 12954 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 629 | 0.210 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 175 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3794 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 2988 | 0.200 |
Why?
|
| Glioblastoma | 1 | 2016 | 3480 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2015 | 1523 | 0.190 |
Why?
|
| Respiratory System Abnormalities | 1 | 2021 | 69 | 0.190 |
Why?
|
| Drug Monitoring | 2 | 2018 | 953 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3591 | 0.180 |
Why?
|
| Fatty Liver | 2 | 2005 | 728 | 0.180 |
Why?
|
| Infectious Disease Medicine | 1 | 2020 | 46 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.180 |
Why?
|
| Phospholipase D | 1 | 2019 | 70 | 0.170 |
Why?
|
| Iceland | 4 | 2020 | 183 | 0.170 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 8856 | 0.170 |
Why?
|
| Genes, cdc | 1 | 2019 | 116 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2015 | 3510 | 0.170 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2003 | 340 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1854 | 0.170 |
Why?
|
| Portugal | 1 | 2018 | 86 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1660 | 0.160 |
Why?
|
| Histiocytosis | 1 | 2018 | 40 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 814 | 0.160 |
Why?
|
| Tidal Volume | 2 | 2019 | 490 | 0.160 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 161 | 0.160 |
Why?
|
| Posture | 3 | 2017 | 957 | 0.160 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2015 | 58 | 0.160 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 213 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2003 | 981 | 0.160 |
Why?
|
| Total Lung Capacity | 3 | 2015 | 143 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 252 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 2039 | 0.150 |
Why?
|
| Thailand | 1 | 2018 | 299 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5691 | 0.150 |
Why?
|
| Benzeneacetamides | 1 | 2017 | 39 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10477 | 0.150 |
Why?
|
| Patient Care Management | 1 | 2021 | 306 | 0.150 |
Why?
|
| Professional Competence | 1 | 2020 | 447 | 0.150 |
Why?
|
| North America | 1 | 2020 | 1249 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2021 | 10251 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8637 | 0.140 |
Why?
|
| Polymorphism, Genetic | 3 | 2017 | 4326 | 0.140 |
Why?
|
| Retreatment | 1 | 2018 | 609 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 311 | 0.140 |
Why?
|
| Movement | 3 | 2019 | 1471 | 0.140 |
Why?
|
| Pleural Diseases | 1 | 2017 | 139 | 0.140 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39001 | 0.140 |
Why?
|
| Mammography | 2 | 2005 | 2475 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2018 | 370 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2649 | 0.130 |
Why?
|
| Young Adult | 12 | 2022 | 56392 | 0.130 |
Why?
|
| Receptor, trkA | 1 | 2016 | 164 | 0.130 |
Why?
|
| Asbestos | 1 | 2017 | 251 | 0.130 |
Why?
|
| Hormone Antagonists | 1 | 2015 | 108 | 0.130 |
Why?
|
| Prednisolone | 1 | 2016 | 334 | 0.130 |
Why?
|
| Thyroiditis | 1 | 2015 | 85 | 0.130 |
Why?
|
| Internationality | 1 | 2020 | 1002 | 0.130 |
Why?
|
| Causality | 1 | 2021 | 1275 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2022 | 901 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2016 | 228 | 0.120 |
Why?
|
| Prednisone | 1 | 2019 | 1574 | 0.120 |
Why?
|
| Spirometry | 4 | 2021 | 863 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 388 | 0.120 |
Why?
|
| Lung Volume Measurements | 2 | 2006 | 378 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 950 | 0.120 |
Why?
|
| Remission Induction | 2 | 2019 | 2384 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2010 | 4033 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2018 | 1063 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 305 | 0.120 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 4848 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 729 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2021 | 2615 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2015 | 323 | 0.110 |
Why?
|
| Risk Factors | 10 | 2020 | 72252 | 0.110 |
Why?
|
| Hepatitis | 1 | 2015 | 227 | 0.110 |
Why?
|
| Pyridones | 1 | 2018 | 711 | 0.110 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 319 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 235 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2015 | 4839 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 14714 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2019 | 2016 | 0.110 |
Why?
|
| Thymoma | 1 | 2014 | 186 | 0.110 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 12354 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 104 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1533 | 0.100 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 4183 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 5867 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1206 | 0.100 |
Why?
|
| Venous Thromboembolism | 2 | 2016 | 1670 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 15526 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 2529 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 2944 | 0.100 |
Why?
|
| Hormones | 1 | 2015 | 889 | 0.100 |
Why?
|
| Consensus | 1 | 2020 | 2954 | 0.100 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 749 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2003 | 3280 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2010 | 60 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1171 | 0.090 |
Why?
|
| Pectoralis Muscles | 1 | 2010 | 82 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2015 | 2008 | 0.090 |
Why?
|
| Cysts | 1 | 2015 | 678 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 654 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.090 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 326 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 18027 | 0.090 |
Why?
|
| Terminology as Topic | 2 | 2015 | 1546 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2010 | 233 | 0.090 |
Why?
|
| Vaccination | 1 | 2021 | 3275 | 0.080 |
Why?
|
| Headache | 1 | 2017 | 1224 | 0.080 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5078 | 0.080 |
Why?
|
| Neutrophils | 1 | 2021 | 3718 | 0.080 |
Why?
|
| Age Factors | 8 | 2021 | 18355 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 599 | 0.080 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2022 | 379 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 7908 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2015 | 646 | 0.080 |
Why?
|
| Recurrence | 3 | 2020 | 8337 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 666 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2019 | 2647 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2015 | 1092 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 674 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 20827 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1023 | 0.070 |
Why?
|
| Prospective Studies | 11 | 2019 | 53250 | 0.070 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 12243 | 0.070 |
Why?
|
| Inflammasomes | 1 | 2012 | 496 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11360 | 0.070 |
Why?
|
| Colitis | 1 | 2015 | 1170 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 5264 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 768 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 850 | 0.070 |
Why?
|
| Fetal Organ Maturity | 1 | 2006 | 82 | 0.070 |
Why?
|
| Prevalence | 4 | 2017 | 15211 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2453 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2016 | 4552 | 0.070 |
Why?
|
| Ovarian Cysts | 1 | 2006 | 115 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 640 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 2568 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 1332 | 0.070 |
Why?
|
| Algorithms | 1 | 2006 | 13869 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 991 | 0.070 |
Why?
|
| Cause of Death | 1 | 2016 | 3580 | 0.060 |
Why?
|
| Serous Membrane | 1 | 2005 | 28 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2014 | 1253 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1161 | 0.060 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 13980 | 0.060 |
Why?
|
| Logistic Models | 5 | 2019 | 13404 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 5854 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3320 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2019 | 925 | 0.060 |
Why?
|
| Aging | 2 | 2021 | 8655 | 0.060 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 113 | 0.060 |
Why?
|
| Palliative Care | 1 | 2019 | 3490 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2566 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10179 | 0.060 |
Why?
|
| Myometrium | 1 | 2005 | 181 | 0.060 |
Why?
|
| Ligands | 2 | 2021 | 3281 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6170 | 0.060 |
Why?
|
| ROC Curve | 3 | 2017 | 3527 | 0.060 |
Why?
|
| Syndrome | 1 | 2010 | 3249 | 0.060 |
Why?
|
| Thrombosis | 1 | 2017 | 2968 | 0.060 |
Why?
|
| Cartilage Diseases | 1 | 2005 | 160 | 0.060 |
Why?
|
| Outpatients | 1 | 2011 | 1488 | 0.060 |
Why?
|
| Torsion Abnormality | 1 | 2003 | 93 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15067 | 0.050 |
Why?
|
| Angiography | 2 | 2006 | 1638 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2017 | 4232 | 0.050 |
Why?
|
| Mice | 7 | 2018 | 81154 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2003 | 176 | 0.050 |
Why?
|
| Ascites | 1 | 2004 | 344 | 0.050 |
Why?
|
| Traction | 1 | 2022 | 106 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2010 | 785 | 0.050 |
Why?
|
| Endometrium | 1 | 2005 | 423 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 3503 | 0.050 |
Why?
|
| Rupture | 1 | 2003 | 433 | 0.050 |
Why?
|
| United States | 4 | 2020 | 69859 | 0.050 |
Why?
|
| Computer-Assisted Instruction | 1 | 2005 | 365 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2005 | 669 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2016 | 4599 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 182 | 0.050 |
Why?
|
| Linear Models | 3 | 2019 | 5952 | 0.050 |
Why?
|
| Models, Biological | 2 | 2018 | 9582 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 686 | 0.050 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 836 | 0.050 |
Why?
|
| Sucrose | 1 | 2021 | 164 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2014 | 5986 | 0.050 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 8 | 0.050 |
Why?
|
| Pericardium | 1 | 2004 | 667 | 0.040 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 176 | 0.040 |
Why?
|
| Airway Obstruction | 1 | 2005 | 662 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 47 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3547 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2265 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2002 | 475 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2004 | 523 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2369 | 0.040 |
Why?
|
| Camptothecin | 1 | 2022 | 576 | 0.040 |
Why?
|
| Fetus | 1 | 2006 | 1880 | 0.040 |
Why?
|
| Endometriosis | 1 | 2006 | 838 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2012 | 5021 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5100 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 6773 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17439 | 0.040 |
Why?
|
| Biopsy | 1 | 2010 | 6750 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21733 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3874 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7172 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2019 | 438 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2015 | 6457 | 0.040 |
Why?
|
| Animals | 7 | 2018 | 168660 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2021 | 594 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3255 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2003 | 1064 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 16674 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15142 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 323 | 0.030 |
Why?
|
| Telomere | 1 | 2022 | 910 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2021 | 9848 | 0.030 |
Why?
|
| Genotype | 3 | 2017 | 12944 | 0.030 |
Why?
|
| X-Rays | 1 | 2016 | 301 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 948 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1186 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 1100 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2021 | 861 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 537 | 0.030 |
Why?
|
| Fever | 1 | 2003 | 1616 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 49 | 0.030 |
Why?
|
| Bronchography | 2 | 2005 | 74 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 561 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.030 |
Why?
|
| Breast | 1 | 2003 | 1970 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2016 | 339 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2019 | 689 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 318 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2015 | 647 | 0.030 |
Why?
|
| Immune System | 1 | 2019 | 807 | 0.030 |
Why?
|
| Apoptosis | 2 | 2020 | 9718 | 0.030 |
Why?
|
| Vitamin K | 1 | 2016 | 295 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 2542 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8430 | 0.030 |
Why?
|
| Pregnancy | 3 | 2006 | 29140 | 0.030 |
Why?
|
| Motion | 1 | 2016 | 798 | 0.030 |
Why?
|
| Methotrexate | 1 | 2019 | 1726 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 552 | 0.030 |
Why?
|
| Internet | 1 | 2005 | 3058 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 3574 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 531 | 0.030 |
Why?
|
| Registries | 2 | 2019 | 8090 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 902 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 1917 | 0.020 |
Why?
|
| Codon | 1 | 2013 | 611 | 0.020 |
Why?
|
| Sex Factors | 2 | 2015 | 10394 | 0.020 |
Why?
|
| Problem Solving | 1 | 2014 | 440 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 224 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1654 | 0.020 |
Why?
|
| Chemokines | 1 | 2015 | 968 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 512 | 0.020 |
Why?
|
| DNA Repair | 1 | 2020 | 2045 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 718 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3128 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1888 | 0.020 |
Why?
|
| DNA Damage | 1 | 2020 | 2429 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2019 | 2575 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2019 | 2107 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1937 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 1338 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2012 | 755 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2017 | 1826 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 646 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2617 | 0.020 |
Why?
|
| Life Style | 1 | 2020 | 3833 | 0.020 |
Why?
|
| China | 1 | 2015 | 2243 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 2938 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 610 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2013 | 2839 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9310 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 4803 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2015 | 12718 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1794 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3740 | 0.020 |
Why?
|
| Patient Selection | 1 | 2019 | 4210 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7479 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4931 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2015 | 2037 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 895 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3089 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 1059 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 1374 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 826 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 1642 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5445 | 0.020 |
Why?
|
| Floxuridine | 1 | 2005 | 49 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 2715 | 0.020 |
Why?
|
| Tegafur | 1 | 2005 | 49 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6620 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Iopamidol | 1 | 2005 | 191 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1639 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8436 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 1524 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2583 | 0.020 |
Why?
|
| Programming Languages | 1 | 2005 | 133 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 1182 | 0.020 |
Why?
|
| Venules | 1 | 2004 | 165 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 2074 | 0.010 |
Why?
|
| Uracil | 1 | 2005 | 165 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2018 | 23398 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 2727 | 0.010 |
Why?
|
| Cytokines | 1 | 2019 | 7324 | 0.010 |
Why?
|
| Massachusetts | 1 | 2017 | 8660 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2019 | 3308 | 0.010 |
Why?
|
| Research Design | 1 | 2019 | 5983 | 0.010 |
Why?
|
| Sarcoma | 1 | 2015 | 1898 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 551 | 0.010 |
Why?
|
| Endosonography | 1 | 2006 | 610 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3706 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 2217 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 1415 | 0.010 |
Why?
|
| Systems Integration | 1 | 2004 | 440 | 0.010 |
Why?
|
| Uterus | 1 | 2006 | 711 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2004 | 674 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2021 | 12209 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12788 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 13809 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12259 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1619 | 0.010 |
Why?
|
| Radiology Department, Hospital | 1 | 2004 | 412 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15518 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 2899 | 0.010 |
Why?
|
| Glioma | 1 | 2015 | 3401 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 18107 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4974 | 0.010 |
Why?
|
| Time Factors | 1 | 2021 | 40038 | 0.010 |
Why?
|
| Trachea | 1 | 2005 | 1076 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2006 | 1928 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2005 | 1431 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 3488 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 3480 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6485 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 9944 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25032 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 21824 | 0.010 |
Why?
|
| Adolescent | 2 | 2006 | 85729 | 0.000 |
Why?
|